The European Commission has approved Merck's (NYSE: MRK) Keytruda (pembrolizumab) in combination with Padcev (enfortumab vedotin-ejfv) as a perioperative treatment ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE